Studies reviewed within this submission: None submitted

Studies reviewed under NDA 22-249:

4.2.1 Pharmacology

4.2.1.1 Primary Pharmacodynamics

4.2.1.1.1 Effect of Bendamustine on Different Human Tumour Cell Lines In vitro. Study 0640.00.C7.04.
4.2.1.1.5 Cell Cycle Alterations by Bendamustine in Comparison with Other Cytotoxic Agents. Study 0640.00.C7.01.
4.2.1.1.6 The Efficacy of Bendamustine is Slightly Decreased by P-glycoprotein and MXR/BCRP Resistance Mechanisms. Study 0640.00.C7.02
4.2.1.1.9 Bendamustine Hydrochloride and the Antitumor Drug Screen Program of the National Cancer Institutes (NCI). Study F-DE-NCI-2004.
4.2.1.1.7 Analysis of the Cytotoxic Potential of Bendamustine Hydrochloride on Human Lymphocytes as Compared to its Degradation and By-Products. Study 744303.
4.2.1.1.8 Analysis of the Cytotoxic Potential of Bendamustine Hydrochloride on Tumor Cell Lines as Compared to its Degradation Products. Study 754900.
4.2.1.1.10 Analysis of the Cytotoxic Potential of Bendamustine Hydrochloride on Tumor Cell Lines as Compared to its Metabolite N-Desmethyl Bendamustine. Study 789401
4.2.1.1.11 Analysis of the Cytotoxic Potential of Bendamustine Hydrochloride on Tumor cell Lines as Compared to its Metabolite N-Desmethyl Bendamustine. Study 789403.
4.2.1.1.12 Effect of Bendamustine Hydrochloride By-Products and Beta-OH-Bendamustine on Tumour Cell Growth. Study 0640.01.C07.06.
4.2.1.1.13 Efficacy of Bendamustine Hydrochloride on the Human Mammary Carcinoma MDA-MB 231 in the NMRI nu/nu Mouse after Intravenous Treatment. Study 0640.00.C8.02.
4.2.1.1.14 Efficacy of Bendamustine Hydrochloride on the Human Lung Carcinoma LX-1 in the NMRI nu/nu Mouse after Intravenous Treatment. Study 0640.00.C08.01.
4.2.1.1.15 Efficacy of SDX-105 and Rituxan in a Xenograft Model of Daudi in SCID Mice. Study T124.
4.2.1.1.16 Dose Response of SDX-105 and SDX-101 in a Xenograft Model of Daudi in SCID Mice. Study T110.
4.2.1.2 Secondary Pharmacodynamics

4.2.1.2.1 Effect of Bendamustine Hydrochloride on Different Non-Malignant Cells of Mice and Humans in Comparison to Other Well-Known Cytostatic Drugs. Study 0640.01.C07.07.
4.2.1.2.2 Determination of the Cytotoxic Potential of SDX-105 in Cultured Human Hepatocytes after In vitro Exposure. Study DM-2005-002.
4.2.1.1.12 Cytotoxicity Assay In vitro with BALB/C3T3 Cells: Neutral Red (NR) Test with Bendamustine Hydrochloride at Simultaneous Irradiation with Artificial Sunlight. Study 789402.

4.2.1.3 Safety Pharmacology

4.2.1.3.1 Evaluation of Effect on Urine Output, Urinary Electrolyte Balance and Glomerular Filtration Rate in the Rat with a Saline Overload Following Two Successive 30-Minute Intravenous Infusions. Study 20010337 PGR.
4.2.1.3.2 Evaluation of Effect on Cardiac Action Potential in Isolated Canine Purkinje Fibers. Study 20010339 PECM.
4.2.1.3.3 Bendamustine Hydrochloride: Effects on HERG-1 Tail Currents Recorded from Stably Transfected HEK 293 Cells. Study 853896.

4.2.1.4 Pharmacodynamic Drug Interactions. N/A

4.2.2 Pharmacokinetics

4.2.2.1 Analytical Methods and Validation Reports

4.2.2.1.1 Validation of a High Performance Liquid Chromatographic Method for the Measurement of Bendamustine and Two Major Metabolites in Dog Plasma and Urine. Study KLG-09.

4.2.2.2 Absorption

4.2.2.2.1 Studies on the Pharmacokinetics of Bendamustine [14C] in the Rat. Study DM-2006-012.

4.2.2.3 Distribution

4.2.2.3.1 Disposition of 14C-Bendamustin in Mice and Rats. Study DM-2007-001.
4.2.2.3.2 The Tissue Distribution of Total Radioactivity in the Rat Following Intravenous Administration of [14C]-CEP-18083. Study DM-2005-006.
4.2.2.3.3 The Tissue Distribution of Total Radioactivity in the Pigmented Rat Following Intravenous Administration of \[^{14}\text{C}]\text{-CEP-18083.HCl}\) (Quantitative Whole Body Autoradiography). Study Am 02 DM-2005-007.

4.2.2.3.4 Excretion and Distribution Studies of \(^{14}\text{C}\)-Bendamustin in the Dog. Study KLG-05.

4.2.2.4 Metabolism

4.2.2.4.1 In vitro Evaluation of CEP-18083 (Bendamustine) as an Inducer of Cytochrome P450 Expression in Cultured Human Hepatocytes. Study DM-2005-004.

4.2.2.4.2 In vitro Metabolism studies of \(^{14}\text{C}\)-Bendamustin. Study 99-37-KLG-01.

4.2.2.4.4 In vitro Plasma Protein Binding Studies of Bendamustine. Study KLG-06.

4.2.2.4.3 Metabolic Profile of \(^{14}\text{C}\)-CEP-18083 (Bendamustine) in Rat Urine and Bile: Preliminary Structural Identification of Metabolites. Study DM-2006-002.

4.2.2.5 Excretion

4.2.2.5.1 The Disposition of \(^{14}\text{C}\)-CEP-18083 in the Rat Following Intravenous Administration. Study Am 01 DM-2005-005.pdf

4.2.2.6 Pharmacokinetic Drug Interactions: N/A

4.2.2.7 Other Pharmacokinetic Studies: N/A

4.2.3 Toxicology

4.2.3.1 Single Dose Toxicity Studies

4.2.3.1.1 Bendamustine Single-Dose Toxicity Study in Mice and Rats. Haertl 1989.

4.2.3.2 Repeat Dose Toxicity Studies

4.2.3.2.1 5-Day Intermittent Intravenous Infusion Dose Range Finding Toxicity Study with CEP-18083 (Bendamustine) in Rats with a 16-Day Recovery Period. Study DS-2006-011.

4.2.3.2.2 15-Week Intermittent Intravenous Infusion Toxicity and Toxicokinetic Study with CEO-18083 (Bendamustine) in Rats with a 4-Week Recovery Period. Study DS-2006-010.

4.2.3.2.5 Bendamustine One-Month Oral Toxicity Study in Rats. Horn et al 1984.

4.2.3.2.6 Bendamustine 3-Months Oral Toxicity Study in Rats. Janowski 1985

4.2.3.2.3 Bendamustine Hydrochloride Maximum Tolerated Dose and Five Day Repeated Dose Study in Dogs by Intravenous Infusion. Study 0640.98.C2.01.

4.2.3.2.4 Bendamustine Hydrochloride Toxicity to Dogs by Daily Intravenous Infusion Over a Minimum of Three 4-Day Cycles Each Followed by a Period Without Treatment of up to 31 Days. Study 0640.98.C2.02.
4.2.3.3 Genotoxicity Studies

4.2.3.3.1 Bendamustine Hydrochloride Bacterial Mutation Assay. Study 0640.00.C4.01.
4.2.3.3.2 Bendamustine Hydrochloride In vitro Mammalian Chromosome Aberration Test in Human Lymphocytes. Study 0640.00.C4.02.
4.2.3.3.3 CEP-18083: Rat Bone Marrow Erythrocyte Micronucleus Test. Study DS-2007-001.
4.2.3.3.4 Chromosome Aberration Test in Human Lymphocytes In vitro with Hydroxy-Bendamustine (HP1). Study 831200.

4.2.3.4 Carcinogenicity: N/A

4.2.3.5 Reproductive and Developmental Toxicity: N/A

4.2.3.6 Local Tolerance

4.2.3.6.1 Perivenous and Intra-Arterial Tolerance Study in the Rabbit. Study 0640.00.C14.01.

4.2.3.7 Other Toxicity Studies:

4.2.3.1.2 Estimate the LD₉₀ Value of Dihydroxy Bendamustine Ethyl Ester (HBI) in Female BDF-1 Mice. Study PT-V1V-108.

4.3 Literature References

Carcinogenicity:


Reproductive and Developmental Toxicity:

Embryofetal Development

Labeling Review

The sponsor has proposed to keep the same Pharmacology/Toxicology (P/T) labeling for TREANDA (NDA 22-303) for NHL and CLL indications as approved by the FDA for TREANDA (NDA 22-249) for CLL indication except for the Mechanism of Action section under CLINICAL PHARMACOLOGY. Their proposal to utilize the same language is acceptable. Our recommendation for the Mechanism of Action section follows the sponsor’s proposed language, and previously approved language by the FDA.

12 CLINICAL PHARMACOLOGY

The sponsor proposed

12.1 Mechanism of Action

Bendamustine is a bifunctional mechloretamine derivative containing a purine-like benzimidazole ring. Mechloretamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells.

The exact mechanism of action of bendamustine remains unknown.

FDA Approved for NDA 22-249.

12.1 Mechanism of Action

Bendamustine is a bifunctional mechloretamine derivative. Mechloretamine and its derivatives dissociate into electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties. The bifunctional covalent linkage can lead to cell death via several pathways. The exact mechanism of action of bendamustine remains unknown.

Bendamustine is active against both quiescent and dividing cells.
12.1 Mechanism of Action
Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells.

The exact mechanism of action of bendamustine remains unknown.

Rationale

Deleted extra words for clarity and discourage promotional statements like [b] (4)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

-------------------
Anwar Goheer
10/22/2008 01:27:53 PM
PHARMACOLOGIST

Leigh Verbois
10/22/2008 01:39:16 PM
PHARMACOLOGIST